# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-119100
Filing Date
2024-10-30
Accepted
2024-10-30 17:03:26
Documents
54
Period of Report
2024-09-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | lrmr-20240930.htm iXBRL | 10-Q | 1542296
2 | EX-31.1 | lrmr-ex31_1.htm | EX-31.1 | 10913
3 | EX-31.2 | lrmr-ex31_2.htm | EX-31.2 | 11009
4 | EX-32.1 | lrmr-ex32_1.htm | EX-32.1 | 16423
| Complete submission text file | 0000950170-24-119100.txt |  | 6841705

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
5 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | lrmr-20240930.xsd | EX-101.SCH | 949005
57 | EXTRACTED XBRL INSTANCE DOCUMENT | lrmr-20240930_htm.xml | XML | 1214730

Mailing Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004
Business Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004 844-511-9056
Larimar Therapeutics, Inc. (Filer) CIK: 0001374690 (see all company filings)

EIN.: 203857670 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36510 | Film No.: 241411289
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)